JP2012529281A - 抗ＥｐＣＡＭ抗体 - Google Patents

抗ＥｐＣＡＭ抗体 Download PDF

Info

Publication number
JP2012529281A
JP2012529281A JP2012514538A JP2012514538A JP2012529281A JP 2012529281 A JP2012529281 A JP 2012529281A JP 2012514538 A JP2012514538 A JP 2012514538A JP 2012514538 A JP2012514538 A JP 2012514538A JP 2012529281 A JP2012529281 A JP 2012529281A
Authority
JP
Japan
Prior art keywords
antibody
seq
sequence
epcam
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012514538A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012529281A5 (enExample
Inventor
ガンナーソン， ラヴィニア ディアナ シコータス
ディドゥリク パウス，
ジェニー マルガレタ カールソン，
レンコ アルバート グリエプ，
セルゲジュ ミチャイロヴィク キプリジャノヴ，
Original Assignee
アフィテック リサーチ エイエス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アフィテック リサーチ エイエス filed Critical アフィテック リサーチ エイエス
Publication of JP2012529281A publication Critical patent/JP2012529281A/ja
Publication of JP2012529281A5 publication Critical patent/JP2012529281A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2012514538A 2009-06-09 2010-06-09 抗ＥｐＣＡＭ抗体 Pending JP2012529281A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US18538709P 2009-06-09 2009-06-09
US61/185,387 2009-06-09
GB0909904.5 2009-06-09
GBGB0909904.5A GB0909904D0 (en) 2009-06-09 2009-06-09 Product
PCT/GB2010/050969 WO2010142990A1 (en) 2009-06-09 2010-06-09 ANTI-EpCAM ANTIBODIES

Publications (2)

Publication Number Publication Date
JP2012529281A true JP2012529281A (ja) 2012-11-22
JP2012529281A5 JP2012529281A5 (enExample) 2013-07-25

Family

ID=40937119

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012514538A Pending JP2012529281A (ja) 2009-06-09 2010-06-09 抗ＥｐＣＡＭ抗体

Country Status (8)

Country Link
US (1) US8637017B2 (enExample)
EP (1) EP2440580A1 (enExample)
JP (1) JP2012529281A (enExample)
CN (1) CN102549017A (enExample)
BR (1) BRPI1011005A2 (enExample)
EA (1) EA201171463A1 (enExample)
GB (1) GB0909904D0 (enExample)
WO (1) WO2010142990A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016510755A (ja) * 2013-03-06 2016-04-11 メリマック ファーマシューティカルズ インコーポレーティッド 抗Ｃ−ＭＥＴタンデムＦｃ二重特異性抗体
JP2020515262A (ja) * 2017-03-29 2020-05-28 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 共刺激ｔｎｆ受容体のための二重特異性抗原結合分子
JP2022506072A (ja) * 2018-10-26 2022-01-17 イミュノジェン， インコーポレイテッド ＥｐＣＡＭ抗体、活性化可能抗体、および免疫複合体、ならびにそれらの使用

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2829283T3 (en) 2003-04-30 2017-09-18 Univ Zuerich METHOD OF TREATING CANCER USING IMMUNOTOXIN
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
NZ601022A (en) 2006-10-12 2014-09-26 Chugai Pharmaceutical Co Ltd Diagnosis and treatment of cancer using anti-ereg antibody
EP2436397B1 (en) 2009-05-29 2017-05-10 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition containing antagonist of egf family ligand as component
US9402916B2 (en) 2011-03-17 2016-08-02 The University Of Birmingham Re-directed immunotherapy
WO2012158818A2 (en) 2011-05-16 2012-11-22 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
TWI593705B (zh) * 2011-12-28 2017-08-01 Chugai Pharmaceutical Co Ltd Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient
CN104168916B (zh) * 2012-03-02 2017-07-04 中央研究院 抗上皮细胞黏着分子(EpCAM)抗体及其使用方法
LT2897978T (lt) * 2012-09-19 2017-06-12 Abbvie Biotherapeutics Inc. Antikūnų su sumažintu imunogeniškumu identifikavimo būdas
CN103387988B (zh) * 2012-09-24 2016-01-06 厦门大学 上皮细胞粘附分子的核酸适体EpCAM Ccut及其制备方法
US20140248292A1 (en) * 2013-03-04 2014-09-04 Oslo Universitetssykehus Hf Compositions and methods for treating cancer
CN105188762A (zh) * 2013-04-12 2015-12-23 维文蒂阿生物公司 用于肝细胞癌检测和治疗的组合物和方法
CN103275226B (zh) * 2013-06-09 2017-08-29 中国科学技术大学 特异性抗人上皮细胞粘附分子（EpCAM）的单克隆抗体的制备、鉴定及应用
BR112015032414A2 (pt) * 2013-06-24 2017-11-07 Chugai Pharmaceutical Co Ltd agente terapêutico compreendendo anticorpo antiepirregulina humanizado como ingrediente ativo para carcinoma de pulmão de célula não pequena excluindo adenocarcinoma
BR112016007232A2 (en) 2013-10-02 2018-01-23 Viventia Bio Inc. anti-epcam antibodies and methods of use
AU2016228755B2 (en) 2015-03-12 2020-09-10 Viventia Bio Inc. Methods of treatment for EPCAM positive bladder cancer
JP6847846B2 (ja) 2015-03-12 2021-03-24 セセン バイオ，インコーポレイテッド Ｅｐｃａｍ陽性膀胱癌を標的とする投薬戦略
CN116327915A (zh) * 2015-04-03 2023-06-27 佐马技术有限公司 使用TGF-β抑制剂和PD-1抑制剂治疗癌症
EP3328897A1 (en) * 2015-07-31 2018-06-06 Sutro Biopharma, Inc. ANTI-EpCAM ANTIBODIES, COMPOSITIONS COMPRISING ANTI-EpCAM ANTIBODIES AND METHODS OF MAKING AND USING ANTI-EPCAM ANTIBODIES
JP7034489B2 (ja) 2016-03-15 2022-03-14 アイタブメッド （エイチケイ） リミテッド 多重特異性Ｆａｂ融合タンパクおよびその使用
AU2017301826A1 (en) 2016-07-26 2019-03-14 Tessa Therapeutics Ltd. Chimeric antigen receptor
CN107814846A (zh) * 2016-11-14 2018-03-20 杭州华得森生物技术有限公司 针对EpCAM和Cytokeratin5的特异性抗体及其制备方法
EP3925976A1 (en) * 2017-09-07 2021-12-22 Dragonfly Therapeutics, Inc. Proteins binding nkg2d, cd16 and a tumor-associated antigen
SG11202007482WA (en) 2018-02-08 2020-09-29 Dragonfly Therapeutics Inc Antibody variable domains targeting the nkg2d receptor
SG11202007579TA (en) 2018-02-08 2020-09-29 Dragonfly Therapeutics Inc Combination therapy of cancer involving multi-specific binding proteins that activate natural killer cells
JP7353576B2 (ja) 2018-02-20 2023-10-02 ドラゴンフライ セラピューティクス， インコーポレイテッド Ｃｄ３３、ｎｋｇ２ｄ、及びｃｄ１６に結合する多重特異性結合タンパク質、ならびにその使用方法
CN108484771A (zh) * 2018-04-24 2018-09-04 南京市妇幼保健院 EpCAM单域抗体G7
JPWO2019244973A1 (ja) 2018-06-20 2021-07-08 中外製薬株式会社 標的細胞に対する免疫反応を活性化する方法およびその組成物
GB201811410D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd OX40 Binding molecules
WO2020018964A1 (en) 2018-07-20 2020-01-23 Fred Hutchinson Cancer Research Center Compositions and methods for controlled expression of antigen-specific receptors
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
EP3833385A4 (en) 2018-08-08 2021-12-22 Dragonfly Therapeutics, Inc. PROTEINS THAT BINDING NKG2D, CD16 AND A TUMOR-ASSOCIATED ANTIGEN
EP3833392A4 (en) 2018-08-08 2022-05-18 Dragonfly Therapeutics, Inc. MULTISPECIFIC BINDING PROTEINS FOR BINDING CD33, NKG2D AND CD16 AND METHODS OF USE
US12460000B2 (en) 2018-09-07 2025-11-04 Itabmed (Hk) Limited Anti-CD19 and anti-CD3 bispecific antigen binding proteins and uses thereof
EP3897851A2 (en) 2018-12-17 2021-10-27 Revitope Limited Twin immune cell engager
WO2020132810A1 (en) 2018-12-24 2020-07-02 Generon (Shanghai) Corporation Ltd. Multispecific antigen binding proteins capable of binding cd19 and cd3, and use thereof
CN113597432B (zh) * 2019-04-22 2023-05-02 江苏恒瑞医药股份有限公司 抗EpCAM抗体及其应用
CN110950959B (zh) * 2020-02-25 2020-07-03 和铂医药(上海)有限责任公司 靶向EpCAM的抗体及其制备和应用
CN118063614A (zh) * 2020-03-11 2024-05-24 南京融捷康生物科技有限公司 可特异性结合EpCAM的单域抗体及其应用
CN115836088A (zh) 2020-05-06 2023-03-21 蜻蜓疗法股份有限公司 结合nkg2d、cd16和clec12a的蛋白质
WO2021231237A2 (en) * 2020-05-11 2021-11-18 Augmenta Bioworks, Inc. Antibodies for sars-cov-2 and uses thereof
CN112359052B (zh) * 2020-08-20 2023-01-03 山东兴瑞生物科技有限公司 抗EpCAM嵌合抗原受体的编码基因、制备方法、具有该基因的质粒、免疫细胞及其应用
TW202241967A (zh) * 2021-01-11 2022-11-01 美商索特里亞生物治療藥物公司 基於茚地那韋的化學二聚化ｔ細胞銜接器組成物
WO2022187539A1 (en) 2021-03-03 2022-09-09 Dragonfly Therapeutics, Inc. Methods of treating cancer using multi-specific binding proteins that bind nkg2d, cd16 and a tumor-associated antigen
AR126009A1 (es) 2021-06-02 2023-08-30 Hoffmann La Roche Moléculas agonistas de unión al antígeno cd28 que se dirigen a epcam
CN113563474B (zh) * 2021-06-11 2023-05-02 广州医科大学附属第三医院（广州重症孕产妇救治中心、广州柔济医院） EpCAM-CD16-NKG2D三特异性抗体及其应用
WO2024082269A1 (zh) * 2022-10-21 2024-04-25 武汉友芝友生物制药股份有限公司 双特异性抗体在免疫细胞治疗方面的应用
TW202506733A (zh) 2023-06-12 2025-02-16 美商安進公司 淋巴毒素β受體促效劑結合蛋白
CN119409829B (zh) * 2024-11-15 2025-08-22 康元医疗科技(大连)有限公司 抗EpCAM纳米抗体及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004533248A (ja) * 2001-05-03 2004-11-04 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング 腫瘍特異的組換え抗体およびその使用
US7227002B1 (en) * 1997-04-14 2007-06-05 Micromet Ag Human antibodies that bind human 17-A1/EpCAM tumor antigen
WO2008122551A2 (en) * 2007-04-04 2008-10-16 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Anti-epcam antibody and uses thereof
JP2009511521A (ja) * 2005-10-11 2009-03-19 ミクロメット・アクチェンゲゼルシャフト 交差種特異的（ｃｒｏｓｓ−ｓｐｅｃｉｅｓ−ｓｐｅｃｉｆｉｃ）抗体を含む組成物および該組成物の使用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2437213A1 (fr) 1978-09-28 1980-04-25 Cm Ind Produits cytotoxiques formes par liaison covalente de la chaine a de la ricine avec un anticorps et leur procede de preparation
US4736866B1 (en) 1984-06-22 1988-04-12 Transgenic non-human mammals
WO1990010457A1 (en) 1989-03-14 1990-09-20 New York University Method of treating hiv infections using immunotoxins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
WO1993017715A1 (en) 1992-03-05 1993-09-16 Board Of Regents, The University Of Texas System Diagnostic and/or therapeutic agents, targeted to neovascular endothelial cells
US5776427A (en) 1992-03-05 1998-07-07 Board Of Regents, The University Of Texas System Methods for targeting the vasculature of solid tumors
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US8236561B2 (en) 1999-04-15 2012-08-07 Crucell Holland B.V. Efficient production of IgA in recombinant mammalian cells
GB9911569D0 (en) 1999-05-18 1999-07-21 Oxford Biomedica Ltd Antibodies
CA2396029A1 (en) 1999-12-27 2001-07-05 Crucell Holland B.V. Use of a native epitope for selecting evolved binding members from a library of mutants of a protein capable of binding to said epitope
DE10143106C1 (de) 2001-09-03 2002-10-10 Artus Ges Fuer Molekularbiolog Vermehrung von Ribonukleinsäuren
CN1812999A (zh) * 2003-05-31 2006-08-02 麦克罗梅特股份公司 包含EpCAM特异构建体的药物组合物
US8802442B2 (en) 2011-11-30 2014-08-12 Eric B. Wheeldon Apparatus and method for the remote sensing of blood in human feces and urine

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7227002B1 (en) * 1997-04-14 2007-06-05 Micromet Ag Human antibodies that bind human 17-A1/EpCAM tumor antigen
JP2004533248A (ja) * 2001-05-03 2004-11-04 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング 腫瘍特異的組換え抗体およびその使用
JP2009511521A (ja) * 2005-10-11 2009-03-19 ミクロメット・アクチェンゲゼルシャフト 交差種特異的（ｃｒｏｓｓ−ｓｐｅｃｉｅｓ−ｓｐｅｃｉｆｉｃ）抗体を含む組成物および該組成物の使用
WO2008122551A2 (en) * 2007-04-04 2008-10-16 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Anti-epcam antibody and uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JPN5012014465; ＬＵＴＴＥＲＢＵＥＳＥ　ＰＥＴＲＡ: 'ＥＸＣＨＡＮＧＩＮＧ　ＨＵＭＡＮ　ＦＣgamma１　ＷＩＴＨ　ＭＵＲＩＮＥ　ＦＣgamma２Ａ　ＨＩＧＨＬＹ　ＰＯＴＥＮＴＩＡＴＥＳ　ＡＮＴＩ-ＴＵＭＯＲ　ＡＣＴＩＶＩＴＹ　以下備考' ＣＡＮＣＥＲ　ＩＭＭＵＮＯＬＯＧＹ　ＩＭＭＵＮＯＴＨＥＲＡＰＹ Ｖ５６　Ｎ４, 200704, Ｐ４５９-４６８ *
JPN5012014470; ＲＡＵＭ　Ｔ: 'ＡＮＴＩ-ＳＥＬＦ　ＡＮＴＩＢＯＤＩＥＳ　ＳＥＬＥＣＴＥＤ　ＦＲＯＭ　Ａ　ＨＵＭＡＮ　ＩＧＤ　ＨＥＡＶＹ　ＣＨＡＩＮ　ＲＥＰＥＲＴＯＩＲＥ：　Ａ　ＮＯＶＥＬ　ＡＰＰＲＯＡＣＨ　以下備考' ＣＡＮＣＥＲ　ＩＭＭＵＮＯＬＯＧＹ　ＡＮＤ　ＩＭＭＵＮＯＴＨＥＲＡＰＹ Ｖ５０　Ｎ３, 20010501, Ｐ１４１-１５０, ＳＰＲＩＮＧＥＲ-ＶＥＲＬＡＧ *
JPN6014042231; Ｂｒ．　Ｊ．　Ｃａｎｃｅｒ，　２００５，　９２（２），　ｐｐ．３４２-３４９ *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016510755A (ja) * 2013-03-06 2016-04-11 メリマック ファーマシューティカルズ インコーポレーティッド 抗Ｃ−ＭＥＴタンデムＦｃ二重特異性抗体
JP2020515262A (ja) * 2017-03-29 2020-05-28 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 共刺激ｔｎｆ受容体のための二重特異性抗原結合分子
JP7196094B2 (ja) 2017-03-29 2022-12-26 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 共刺激ｔｎｆ受容体のための二重特異性抗原結合分子
US11639394B2 (en) 2017-03-29 2023-05-02 Hoffmann-La Roche Inc. Bispecific antigen binding molecule for a costimulatory TNF receptor
JP2022506072A (ja) * 2018-10-26 2022-01-17 イミュノジェン， インコーポレイテッド ＥｐＣＡＭ抗体、活性化可能抗体、および免疫複合体、ならびにそれらの使用
JP7592009B2 (ja) 2018-10-26 2024-11-29 イミュノジェン， インコーポレイテッド ＥｐＣＡＭ抗体、活性化可能抗体、および免疫複合体、ならびにそれらの使用

Also Published As

Publication number Publication date
BRPI1011005A2 (pt) 2018-03-06
GB0909904D0 (en) 2009-07-22
WO2010142990A1 (en) 2010-12-16
CN102549017A (zh) 2012-07-04
US20100310463A1 (en) 2010-12-09
US8637017B2 (en) 2014-01-28
EP2440580A1 (en) 2012-04-18
EA201171463A1 (ru) 2012-07-30

Similar Documents

Publication Publication Date Title
US8637017B2 (en) Anti-EpCAM antibodies
US8822664B2 (en) Antibodies
US9353185B2 (en) Antibodies
AU2011340264B2 (en) Anti CCR4 antibodies and uses thereof
US20090070890A1 (en) Product
WO2017071625A1 (zh) 一种抗pd-1单克隆抗体、其药物组合物及其用途
US10266599B2 (en) Antibodies which bind to the human CC chemokine receptor 4 and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130606

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130606

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20141007

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20141222

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150205

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150306

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150609